玻璃体腔注射雷珠单抗治疗老年性湿性黄斑病变疗效观察

doi:10.3969/j.issn.1006-6233.2017.09.028

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (1437 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the efficacy of vitreous cavity injection in the treatment of senile wet macular degeneration. Methods: 90 elderly patients with age-related wet macular degeneration who were enrolled from May 2014 to May 2016 were randomly divided into three groups. Group A was given vitreous cavity injection of ranibizumab and photocoagulation. Group B patients were given only ranibizumab injection the patients were given only photocoagulation in group C, and the best corrected visual acuity, central macular thickness and the trend and complication were compared between the three groups. Results: Compared with group B and group C, the difference between 1m, 3m, 6m and 12mBCVA scores was significantly higher than that of group B and group C (P <0.01). There was a significant difference between the two groups (P <0.01). There was a significant difference between the two groups (P <0.05) |There was no significant difference in the incidence of complications between the three groups (P>|0.05). Conclusion: Vitreous cavity injection of ranibizumab photocoagulation in the treatment of senile wet macular degeneration in the most significant effect, high safety, with reference.

Key words： Leopard monoclonal antibody Wet macular degeneration Best corrected visual acuity Central macular thickness

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAO Xuelian

Cite this article:

HAO Xuelian. Clinical Observation of Vitreous Cavity Injection of Ranibizumab in the Treatment of Wet Age-related Macular Degeneration[J]. 河北医学, 2017, 23(9): 1502-1505.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.09.028 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I9/1502

[1] 薛山,陈鹏.糖尿病黄斑水肿应用玻璃体内注射雷珠单抗、曲安奈德的疗效分析[J].国际医药卫生导报,2016,22(20):3149~3151.
[2] 李琳娜.玻璃体腔单次注射雷珠单抗治疗糖尿病黄斑水肿与视网膜静脉阻塞性黄斑水肿的短期疗效观察[J].临床眼科杂志,2014,22(6):498~501.
[3] P Kloos H,Niederberger C,Valmaggia. Photodynamic Therapy in "Secondary Sick RPE Syndrome"|after Repeated Intravitreal Injections of VEGF Inhibitors in Patients with Wet Age-Related Macular Degeneration[J].Klin Monatsbl Augenheilkd,2011,228(04): 340~344.
[4] Fardad T, Afshari,Jessica C,et al.Integrin activation or alpha9 expression allows retinal pigmented epithelial cell adhesion on Bruch's membrane in wet age-related macular degeneration[J].Brain,2010,133(2): 448~464.
[5] 董晓萱,韩笑.雷珠单抗玻璃体腔单药注射与联合视网膜激光光凝治疗糖尿病黄斑水肿疗效Meta分析[J].中国实用眼科杂志,2015,33(3):271~275.
[6] Mohammad Hossein Yazdi,Mohammad Ali Faramarzi,Shekoufeh Nikfar,et al.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration[J].Expert Opinion on Biological Therapy,2015,15(9): 1349~1358.
[7] Sushma Kandula,Jeffrey C Lamkin,Teresa Albanese,et al. Patients&apos|knowledge and perspectives on wet age-related macular degeneration and its treatment[J].Clinical Ophthalmology,2010,2010(default): 375.
[8] 刘杰.玻璃体腔注射雷珠单抗治疗糖尿病黄斑水肿与视网膜静脉阻塞性黄斑水肿的疗效对比[J].临床眼科杂志,2015,23(3):220~223.
[9] 付浴东,孟旭霞,王大博,等.雷珠单抗单次玻璃体腔注射对糖尿病黄斑水肿的治疗作用[J].国际眼科杂志,2017,17(3):504~507.
[10] Atul Kumar,Sangeeta Roy,Mayank Bansal,et al. Modified Approach in Management of Submacular Hemorrhage Secondary to Wet Age-Related Macular Degeneration[J].Asia-Pacific Journal of Ophthalmology,2016,5(2): 143~146.
[11] 王博,吴京,马明,等.玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246~249.
[12] 姜虎林,韩旭巍,张生奇,等.玻璃体腔内注射雷珠单抗联合黄斑格栅样光凝治疗糖尿病黄斑水肿[J].国际眼科杂志,2014,14(7):1253~1256.
[13] 杨敏,李燕龙,姜旭光,等.雷珠单抗联合577nm激光黄斑格栅光凝治疗重度糖尿病黄斑水肿[J].国际眼科杂志,2017,17(4):694~697.
[14] 吕勇,范琼艳.老年白内障手术联合玻璃体腔注射雷珠单抗对糖尿病性黄斑水肿影响[J].中国实用眼科杂志,2014,32(5):560~563.
[15] 王海山,张海军,李玉军,等.雷珠单抗玻璃体腔注射并激光光凝治疗糖尿病性黄斑水肿疗效观察[J].中国实用眼科杂志,2015,33(1):25~29.